DrugPatentWatch Database Preview

US Patents With Foreign Priority to United Kingdom Patent: 0601082.1

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use
Novartis	AFINITOR	everolimus	TABLET;ORAL	022334-001	Mar 30, 2009		RX	Yes	No	➤ Sign Up	➤ Sign Up				TREATMENT OF PATIENTS WITH PROGESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) THAT ARE UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC
Novartis	AFINITOR	everolimus	TABLET;ORAL	022334-002	Mar 30, 2009		RX	Yes	Yes	➤ Sign Up	➤ Sign Up				TREATMENT OF PATIENTS WITH PROGESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) THAT ARE UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC
Novartis	AFINITOR	everolimus	TABLET;ORAL	022334-003	Jul 9, 2010		RX	Yes	No	➤ Sign Up	➤ Sign Up				TREATMENT OF PATIENTS WITH PROGESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) THAT ARE UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC
Novartis	AFINITOR	everolimus	TABLET;ORAL	022334-004	Mar 30, 2012		RX	Yes	No	➤ Sign Up	➤ Sign Up				TREATMENT OF PATIENTS WITH PROGESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) THAT ARE UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use